ライフサイエンスコーパス: specific cytotoxicity

1 nhibited HCV RNA replication through antigen-specific cytotoxicity.

2 mma(+), and exhibited HLA-restricted CMVpp65-specific cytotoxicity.

3 , exhibit potent, HLA class I-restricted, GA-specific cytotoxicity.

4 effector mechanisms involved in reovirus 1/L-specific cytotoxicity.

5 l to undergo complement-independent antibody specific cytotoxicity.

6 eptide stimulation, possessed no ex vivo CMV-specific cytotoxicity.

7 the lines obtained were screened for peptide-specific cytotoxicity.

8 f stimulation further enhanced the levels of specific cytotoxicity.

9 d susceptible neonates acquired strong MT389-specific cytotoxicity.

10 g therapy (VDEPT) is its potential for tumor-specific cytotoxicity.

11 indicated that CD8(+) CTL mediated the pp65-specific cytotoxicity.

12 CEA-specific CD4+ responses and CEA peptide-specific cytotoxicity.

13 manner, coincident with restoration of viral-specific cytotoxicity.

14 d lymphocytes frequently lack detectable HIV-specific cytotoxicity.

15 type 2 CD8(+) T-cell subset with reduced EBV-specific cytotoxicity.

16 + T cells are primarily responsible for this specific cytotoxicity.

17 mor infiltrating T cells (T-TILs) lack tumor-specific cytotoxicity.

18 whereas antigen-pulsed APC strongly elicited specific cytotoxicity.

19 These CTLs from MM patients demonstrated specific cytotoxicity (24.7% at the effector-target [E/T

20 tibodies to cell-bound MUC1 SEA domain exert specific cytotoxicity against cancer cells, and they poi

21 Dsg3 CAAR-T cells exhibit specific cytotoxicity against cells expressing anti-Dsg3

22 ed that the resulting CTL cultures possessed specific cytotoxicity against EBV and CMV.

23 tested in human primary NK cells and confers specific cytotoxicity against KIR/HLA-matched PSCA-posit

24 ation of GAB1 and demonstrated potent, tumor-specific cytotoxicity against MDA-MB-231 and T47D breast

25 T cells with specific cytotoxicity against peptides derived from the

26 nctional analysis of the T cell lines showed specific cytotoxicity against syngeneic porcine targets

27 eactivation, RNase A-NBC shows a significant specific cytotoxicity against tumor cells.

28 red with MVAp53, both adjuvants enhanced p53-specific cytotoxicity and demonstrated an additive effec

29 tivation, including how 4-1BB enhances tumor-specific cytotoxicity and how 4-1BB can promote tumor im

30 haracterized by CD8(+) T cell-mediated tumor-specific cytotoxicity and IFN-gamma production, and was

31 these SCID mice restored both, robust tumor-specific cytotoxicity and long-lived T-cell memory, capa

32 Gld and lpr mice demonstrated normal TMEV-specific cytotoxicity and maintained resistance to TMEV-

33 immunotoxin E9(Fv)-PE38 exhibits remarkably specific cytotoxicity and merits further evaluation for

34 gineered HSPCs produced T cells with antigen-specific cytotoxicity and near-complete lack of endogeno

35 ation with a strong correlation between cell-specific cytotoxicity and reciprocal coupling of drug-in

36 nes showed inverse relationships between EBV-specific cytotoxicity and secretion of IL-4, IL-10, and

37 Anti-Tn-MUC1 CAR T cells demonstrated target-specific cytotoxicity and successfully controlled tumor

38 s with tumor cells failed to induce idiotype-specific cytotoxicity, and following vaccination, deplet

39 re than one-third (13/36) demonstrated HIV-1-specific cytotoxicity, and this activity significantly c

40 ase assays were used to evaluate ex vivo CMV-specific cytotoxicity associated with the PBMC samples.

41 inoma model was used to show that insulinoma-specific cytotoxicity can be accomplished by RIP coupled

42 totype to explore the effectiveness of tumor-specific cytotoxicity delivery using a receptor-mediated

43 ys were conducted, and the potential for non-specific cytotoxicity determined.

44 lls were enriched after 3 to 4 weeks and CMV-specific cytotoxicity developed 1 to 2 weeks later.

45 op1-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing r

46 esponsible for down-regulating their antigen-specific cytotoxicity during both viral clearance and vi

47 s as a prodrug via a labile linker with site-specific cytotoxicity for cancer cells bearing these rec

48 ronegative (ES) individuals exhibiting HIV-1-specific cytotoxicity for the presence of HIV-1.

49 ow that the virus preparation exhibiting Fas-specific cytotoxicity has the same density as a retrovir

50 gamma(-/-) CD4 cells exhibit influenza virus-specific cytotoxicity; however, IFN-gamma-deficient CD4

51 e immunotherapy strategy to generate antigen-specific cytotoxicity in brain tumor patients.

52 ne monoclonal antibody 13-1 possesses target-specific cytotoxicity in human PDA cell lines, we design

53 In this report, we demonstrate that the EBV-specific cytotoxicity in the BLCLpp65-primed culture had

54 tence and demyelination in this model, virus-specific cytotoxicity in the CNS of DA-resistant (B6 or

55 bits the generation of H-2K-restricted virus-specific cytotoxicity in the CNS, permitting a persisten

56 ence of anti-donor Ab and Ab-dependent donor-specific cytotoxicity in vitro and intravascular IgM dep

57 lar to CD8(+) effector cells and showed CD20-specific cytotoxicity in vitro.

58 1 hosts exhibited a higher level of melanoma-specific cytotoxicity in vitro.

59 nsulinoma-specific expression and insulinoma-specific cytotoxicity in vitro.

60 g gamma interferon and exerting potent HIV-1-specific cytotoxicity in vitro.

61 cient DCs trigger Th1 differentiation and Ag-specific cytotoxicity in vivo.

62 and human neoplasms, in many instances tumor-specific cytotoxicity is not observed.

63 These results suggest that HIV-1-specific cytotoxicity of CD8(+) T cells is preferentiall

64 Surprisingly, we show that the Ag-specific cytotoxicity of iNKT cells in vivo depended alm

65 erforin/granzyme-mediated mechanisms, the Ag-specific cytotoxicity of iNKT cells in vivo is largely r

66 antigen binding of anti-Tac pFv, and of the specific cytotoxicity of pFv-immunotoxin towards antigen

67 To overcome a non-specific cytotoxicity of STPP-L, we synthesized a novel

68 We determined that tumor-specific cytotoxicity of the poliovirus/rhinovirus chime

69 The purified IT showed specific cytotoxicity on nine different cancer cell line

70 Toxoplasma-infected APC stimulated specific cytotoxicity poorly or not at all, owing to dea

71 HIV-1-specific cytotoxicity remained detectable in most treate

72 Of particular interest, Ks-restricted virus-specific cytotoxicity-restricted CTLs were identified in

73 8+ cytotoxic T cells (CTLs) enriched for HIV-specific cytotoxicity targeted against a diversity of HI

74 lly infected patients displayed less peptide-specific cytotoxicity than those from recovered patients

75 lded a functional toxin and showed cell line specific cytotoxicity that is consistent with heregulin

76 1)Cr release assays to measure ex vivo virus-specific cytotoxicity, the emerging virus-specific CTL r

77 includes cytokine effects and direct antigen-specific cytotoxicity to hematopoietic precursors.

78 tetramer (HLA-A2/MBP(111-119)) and exhibited specific cytotoxicity toward autologous target cells pul

79 Moreover, OK-DC displayed strong, specific cytotoxicity toward tumor cell targets.

80 Insulinoma-specific cytotoxicity using the suicide gene thymidine k

81 ing T(H)1 and T(H)2 cytokines, and may exert specific cytotoxicity via exocytosis of granulysin.

82 incubation with IL-12 for 5 to 7 days, HIV-1-specific cytotoxicity was augmented in a dose-dependent

83 L cells in 51Cr-release cytotoxicity assays, specific cytotoxicity was demonstrable using TILs from d

84 Detection of MC38-specific cytotoxicity was markedly enhanced when murine

85 tides were used to demonstrate that this CMV-specific cytotoxicity was specific for pp65.

86 A mechanism for this leukemia-specific cytotoxicity was suggested by the abnormal over

87 Alloantigen-specific cytotoxicity was tested using 51Cr release assa

88 death machinery to selectively deliver tumor-specific cytotoxicity (while minimizing damage to other

89 nity for FR-positive cells and to provide FR-specific cytotoxicity with an IC(50) in the low nanomola